Bausch + Lomb recently announced the U.S. FDA has accepted the New Drug Application (NDA) for Luminesse™ — a topical vasoconstrictor formulation to be used over-the-counter as an eye drop to relieve ocular redness due to minor eye irritations — and reported updated results of the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) Study.
Upon acceptance of the NDA for Luminesse (brimonidine tartrate ophthalmic solution, 0.025%), B+L also received a PDUFA action date of December 27, 2017. If approved, Luminesse will reportedly be the first OTC product developed with brimonidine tartrate for the treatment of ocular redness.
Click here to read the full press release.
And at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting last week, ARMOR study researchers presented preliminary 2016 surveillance data on antibiotic resistance levels, in addition to an eight-year trend analysis of antibiotic resistance among staphylococcal isolates. According to researchers, while the latest data shows decreases in resistance, resistance to several commonly used antibiotics continues to be a challenge. Researchers believe understanding these resistance trends can help eyecare professional ensure their patients are matched with effective treatments to potentially avoid sight-threatening ocular infections.
Click here to read the full press release.
Like what you read? Follow OptometryWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.